Pharma Journalist -

Novartis announced it has agreed to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 monoclonal antibody designed to…
Read More...

Medison and Ipsen announced that Health Canada has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients aged 12 months and older with Alagille Syndrome…
Read More...

Servier, an international pharmaceutical group, has announced the acquisition of KER-0193, a promising potential treatment for Fragile X syndrome (FXS) from UK-based biotech Kaerus…
Read More...

Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-313 clinical trial evaluating Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic…
Read More...

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with KEYTRUDA…
Read More...

Argo Biopharmaceutical Co., Ltd., a clinical-stage biotech focused on next-generation siRNA therapies, has announced a new strategic collaboration with Novartis to develop multiple…
Read More...

AbbVie announced that Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection) under the Priority Review process. ELAHERE is an antibody-drug conjugate (ADC)…
Read More...

Avadel Pharmaceuticals plc, a biopharmaceutical company dedicated to advancing treatments for sleep disorders, has entered into an exclusive global license agreement with XWPharma Ltd.…
Read More...

The U.S. Food and Drug Administration introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat…
Read More...

Gilead Sciences, Inc. announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's…
Read More...